Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen‐season model of allergic rhinitis

@article{AhlstrmEmanuelsson2004TopicalTW,
  title={Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen‐season model of allergic rhinitis},
  author={C. Ahlstr{\"o}m-Emanuelsson and M. Andersson and C. Persson and C. Schrewelius and L. Greiff},
  journal={Clinical & Experimental Allergy},
  year={2004},
  volume={34}
}
  • C. Ahlström-Emanuelsson, M. Andersson, +2 authors L. Greiff
  • Published 2004
  • Medicine
  • Clinical & Experimental Allergy
  • Background Rofleponide palmitate is an esterified glucocorticosteroid pro‐drug with a promising pre‐clinical profile designed to deliver topical airway treatment for allergic rhinitis and asthma in a novel manner. Thus, the rofleponide palmitate pro‐drug is designed to provide topical exposure of the mucosa to the inactive lipophilic drug, which would be locally metabolized to the more hydrophilic and readily cleared drug rofleponide. 
    21 Citations
    Investigational drugs for the treatment of allergic rhinitis
    • 7
    • Highly Influenced
    Clinical efficacy and pharmacokinetic profiles of intranasal and oral cetirizine in a repeated allergen challenge model of allergic rhinitis.
    • M. Korsgren, M. Andersson, +4 authors L. Greiff
    • Medicine
    • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
    • 2007
    • 13
    New Therapies for Allergic Rhinitis
    • 20
    Investigational drugs for allergic rhinitis
    • 3
    Emerging drugs for perennial allergic rhinitis
    Novel, Alternative, and Controversial Therapies of Rhinitis.
    • 4
    Allergic rhinitis: current options and future perspectives
    • 24
    Does Lipophilicity Per Se Induce Adjuvant Effects? Methyl Palmitate as Model Substance Does Not Affect Ovalbumin Sensitization
    • 10
    Emerging drugs for the treatment of perennial allergic rhinitis
    • 16

    References

    SHOWING 1-10 OF 14 REFERENCES
    Mucosal output of eotaxin in allergic rhinitis and its attenuation by topical glucocorticosteroid treatment
    • L. Greiff, H. Petersen, +5 authors C. Persson
    • Medicine
    • Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
    • 2001
    • 37
    Glucocorticosteroids and rhinitis
    • 82
    Clinical and antiinflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis.
    • E. Meltzer
    • Medicine
    • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
    • 1998
    • 41
    Dose-dependent effects of budesonide aqueous nasal spray on symptoms in a daily nasal allergen challenge model.
    • 22
    Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis.
    • E. Bronsky, D. Aaronson, +15 authors K. Nolop
    • Medicine
    • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
    • 1997
    • 58
    Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid.
    • 22
    Allergen-induced eosinophil cytolysis is a primary mechanism for granule protein release in human upper airways.
    • 133